Intersect ENT (NSDQ:XENT) launched its steroid-releasing sinus implant, Sinuva, in the U.S. today. The company’s drug-eluting device is designed to treat nasal polyp disease in patients who have undergone previous sinus surgery.
Sinuva is placed during a routine doctor’s office visit and releases an anti-inflammatory steroid, mometasone furoate, directly to the patient’s nasal polyps for up to 90 days.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT launches Sinuva steroid-releasing sinus implant appeared first on MassDevice.
from MassDevice https://ift.tt/2Gqdy65
Cap comentari:
Publica un comentari a l'entrada